New methods to measure kidney function in patients with chronic kidney disease
DYNAMic Renal Assessment: NOvel Methods to Assess KIDNEY Functional Reserve
This study is testing new ways to measure kidney function in people with chronic kidney disease to see if they can better predict future problems and how a medication might help.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 44 (estimated) |
| Ages | 40 Years and up |
| Sex | All |
| Sponsor | King's College Hospital NHS Trust Academic / other |
| Locations | 1 site (London) |
| Trial ID | NCT06572215 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate innovative techniques for assessing renal functional reserve in patients with chronic kidney diseases. It focuses on quantifying glomerular filtration rate (GFR) over time, moving beyond traditional static assessments like serum creatinine, which can underestimate kidney function loss. By examining how GFR responds to stimuli such as exercise and protein intake, the study seeks to identify early indicators of reduced renal reserve that may predict future kidney complications. The intervention involves administering dapagliflozin to assess its effects on renal function.
Who should consider this trial
Good fit: Ideal candidates include patients with sickle cell nephropathy or those who have previously donated a kidney, aged 4 and older.
Not a fit: Patients under 40 years old, those unable to provide informed consent, or pregnant/breastfeeding women may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier detection of kidney dysfunction and improved management strategies for patients with chronic kidney disease.
How similar studies have performed: While the approach of assessing renal reserve is innovative, similar methodologies have shown promise in other studies, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion: * Patients with sickle cell nephropathy, diagnosed clinically or histologically. Sickle Cell patients will be confirmed Hb SS and eGFR (CKD-EPI) ≥ 135 ml/min/1.73m2 OR * Previous living kidney donation * Age ≥ 4No contraindication or known allergy to any trial medications. * Willing and able to provide written informed consent Exclusion: * Aged \< 40 * Unable or unwilling to provide informed consent * Breastfeeding or pregnant women * Patients involved in other interventional research studies.
Where this trial is running
London
- King's College Hospital — London, United Kingdom (Recruiting)
Study contacts
- Study coordinator: Kate Bramham, Doctor
- Email: kch-tr.research@nhs.net
- Phone: 0203 299 9000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.